Researchers of the group, French pharmaceutical Sanofi and u.s
national Institutes of health (NIH) have developed a combination of neutralizing antibody to the aids virus triple antiviral presented as extremely promising for the prevention and treatment of the aids virus. Treatment, the details of which were published Wednesday, September 20, in the american journal Science, has been shown to protect macaques against the simian virus of aids (VIS) and of the strains of the human immunodeficiency virus (HIV). A clinical trial of phase 1 should be conducted in 2018 on volunteers healthy and HIV-infected individuals, in order to assess the safety and efficacy of this new molecule.
For this experiment, researchers treated three groups of eight macaques. The first two with, respectively, simple antibodies (VRC01 and PGDM1400), and the third group with the triple antibody. Five days after, the 24 macaques were exposed to two strains of the simian virus of aids, and a combination of HIV.
The majority of the animals of the first two groups, five and six of eight, respectively, were infected.
By contrast, no animal in the third group treated with the triple antibody has not been contaminated, according to the researchers. A great diversity of virusCet antiviral “three heads” has provided a better protection than all of the other antibodies tested so far, neutralizing 99% of the more than 200 different strains of HIV-1, they said.
The new agent was also tested on human cells in the laboratory. These antibodies have been produced through genetic engineering to detect and neutralize multiple targets in infectious simultaneously. “The difference of natural antibodies, this is a triple antiviral hitting targets-infectious multiple in a single molecule,” says Dr.
Gary Nabel, chief scientific officer Sanofi and the main author of this work.
“This approach has the potential to improve the protection against HIV and is also a approach for new treatments against cancer and autoimmune diseases, and infectious”, says the researcher.
“The combination of therapies has already shown its effectiveness against HIV and cancer”, says the virologist. The high genetic diversity of HIV worldwide represents the main difficulty to produce antibodies capable of effectively fighting the current pandemic, point these researchers. “A combination of antibodies, each strike of the distinct sites of the HIV envelope could well be the best approach to neutralize the defenses of the virus, and achieve to produce an anti-infectious therapy and prevention”, was held by the Dr.
Anthony Fauci, director of the us national Institute of allergy and infectious diseases. .